Skip to main content

Advertisement

Table 2 Pooled analysis of functional class, exercise capacity, quality of life, and clinical outcome

From: Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis

  No. of studies Mean difference/risk ratio 95% CI P
6-min walk distance
 Overall 9 53.13 25.47, 81.10 0.0002
 3 months 6 47.92 7.95, 87.89 0.02
 6 months 8 49.68 3.34, 96.01 0.04
 ≥ 12 months 6 63.91 0.06, 127.76 0.05
NYHA functional class
 Overall 6 − 0.48 − 0.65, − 0.31 < 0.0001
 3 months 4 − 0.28 − 0.49, 0.08 0.007
 6 months 4 − 0.52 − 0.96, − 0.07 0.02
 ≥ 12 months 6 − 0.63 − 0.83, − 0.43 < 0.0001
 Peak VO2 4 0.94 − 3.15, 5.02 0.65
 MlHFQ 4 − 18.41 − 29.90, − 6.92 0.002
 MACE 6 0.79 0.60, 1.04 0.09
 Rehospitalization 5 0.71 0.49, 1.04 0.08
 All-cause mortality 17 0.74 0.56, 0.98 0.04
 Cardiovascular death 8 0.65 0.29, 1.46 0.29
  1. NYHA New York Heart Association, MlHFQ Minnesota Living with Heart Failure Questionnaire, MACE major adverse cardiovascular events